What Is Uterine Papillary Serous Carcinoma?

Uterine papillary serous carcinoma (UPSC) is an uncommon but exceptionally aggressive subtype of endometrial cancer. It makes up roughly 10% of all uterine cancer cases yet accounts for about 40% of deaths from the disease, a disparity that sets it apart from the far more common endometrioid type of endometrial cancer.¹ That gap between its frequency and its lethality is what makes UPSC a subject of intense research, and why it is treated quite differently from other uterine cancers once identified.

How UPSC Differs From Typical Endometrial Cancer

Most endometrial cancers are endometrioid adenocarcinomas, which tend to grow slowly, respond well to hormones, and are often caught early because they produce abnormal bleeding while still confined to the uterus. UPSC behaves almost nothing like this. It has a pattern of spread that more closely resembles ovarian serous carcinoma, with a tendency to seed the abdominal cavity, the omentum, and lymph nodes even when the tumor appears small or has barely penetrated the uterine wall.² An estimated 60 to 70% of patients already have metastatic disease at the time they are diagnosed.³

The risk factors also diverge. Endometrioid endometrial cancer is strongly linked to obesity and estrogen exposure, including the use of menopausal hormone therapy. Those associations are weak or absent for UPSC. A study comparing the two types found that high body mass index carried a relative risk of 3.5 for endometrioid cancer and menopausal estrogen use carried a relative risk of 2.4, while serous carcinomas were not strongly associated with either factor.⁴ Instead, clinical risk factors for UPSC include advancing age, a history of breast cancer, tamoxifen use, and hereditary breast-ovarian cancer syndrome.⁵

Symptoms and How It Is Found

The most common symptom is postmenopausal vaginal bleeding, which is also the hallmark of ordinary endometrial cancer. Other symptoms can include pelvic pain, unexplained weight loss, bloating, or feeling a pressure or lump in the pelvis.³ These symptoms are not unique to UPSC, so the diagnosis comes from a biopsy of the uterine lining, typically after an endometrial sampling or dilation and curettage procedure.

Under the microscope, pathologists look for distinctive architectural patterns. The most common growth pattern is a mixture of papillary and other features (seen in about 58% of cases), followed by a pure papillary pattern (about 34%), with solid and diffuse glandular patterns appearing less often.⁶ These details matter because pathologists must distinguish UPSC from high-grade endometrioid cancers, which look somewhat similar but respond to different treatments.

Why It Spreads Before Invading Deeply

One of the most unsettling features of UPSC is that it can spread widely while the primary tumor looks deceptively limited. In endometrioid cancers, the deeper the tumor invades the muscular wall of the uterus, the higher the chance of metastasis. That rule does not reliably hold for UPSC. In a study of 50 women, extrauterine disease was found in 72% of cases. Among women with no myometrial invasion at all, 36% still had lymph node metastases. Neither tumor grade nor depth of invasion predicted whether cancer had escaped the uterus.⁷

The practical consequence of this pattern is that even a tumor that looks early-stage on imaging or on initial pathology can harbor hidden metastatic deposits. About 17% of patients in one surgical series had omental metastases discovered only after the omentum was removed and examined, and roughly one in six patients was upstaged to stage IVB based on routine omentectomy findings that would otherwise have been missed.⁸ This is why surgical staging for UPSC is far more extensive than for typical endometrial cancer. Surgeons generally perform a hysterectomy along with omentectomy, retroperitoneal lymph node dissection, and abdominal washings, similar to the staging done for ovarian cancer.²

Serous Endometrial Intraepithelial Carcinoma

UPSC appears to develop from a precursor lesion called serous endometrial intraepithelial carcinoma (SEIC), sometimes found on the surface of endometrial polyps or in atrophic endometrium.⁹ Despite the word “intraepithelial,” which sounds reassuringly early, SEIC is itself capable of spreading beyond the uterus. The precursor shares the same molecular defects as full-blown UPSC, which helps explain why even apparently early-stage disease can behave aggressively.

The Molecular Profile

The biology driving UPSC is fundamentally different from that of endometrioid endometrial cancer. Where endometrioid tumors tend to accumulate mutations in PTEN, KRAS, and the mismatch repair system, UPSC is overwhelmingly defined by mutations in the TP53 gene, which encodes the p53 protein. Genome-wide analyses have identified TP53 mutations in about 82% of uterine serous carcinomas.¹⁰ Studies using direct gene sequencing have found rates as high as 90%.¹¹

Importantly, the same TP53 mutations appear in the precursor lesion SEIC at nearly the same frequency, suggesting that p53 loss is an initiating event rather than something tumors acquire later as they grow. Not every tumor with abnormal p53 protein staining has an identifiable point mutation in the gene itself. Some tumors show strong p53 protein accumulation without a detectable gene mutation, which points to alternative ways the p53 pathway can be shut down.¹²

Beyond TP53, genome-wide sequencing has identified recurrent mutations in PIK3CA (about 24%), FBXW7 (about 20%), and PPP2R1A (about 18%).¹⁰ These mutations hit signaling pathways that control cell growth and protein turnover, and some have become targets for newer drugs. UPSC also tends to have a low rate of microsatellite instability, which limits the effectiveness of certain immunotherapy approaches that work well in other endometrial cancers.¹³

The Role of HER2

A subset of UPSC tumors overexpress or amplify the HER2 gene, which is better known for its role in breast cancer. Reported rates vary by study, but HER2 overexpression has been found in roughly 18% of tumors in one series, while HER2 gene amplification occurs in around 17% of cases in others.¹⁴ ¹⁵ This matters because it opens the door to targeted therapy with trastuzumab, the same drug used in HER2-positive breast cancer.

A randomized phase II trial showed that adding trastuzumab to carboplatin-paclitaxel chemotherapy improved median progression-free survival from 8 months to about 12.6 months across all patients, with even larger gains in patients with advanced-stage primary disease (9.3 versus 17.9 months).¹⁶ A larger retrospective analysis of 280 patients with advanced HER2-positive disease found that adding trastuzumab pushed median overall survival from about 25 months to 41 months.¹⁷ These results have made HER2 testing a standard part of the workup for UPSC, since the roughly one-in-five patients who are HER2-positive stand to benefit from a drug already widely available.

Standard Treatment

Surgery is the cornerstone: a total hysterectomy with removal of both ovaries and fallopian tubes, plus the comprehensive staging already described. Because of the high risk of hidden spread, most patients receive additional treatment even when surgery appears to have removed all visible disease.

The most commonly used chemotherapy regimen is carboplatin combined with paclitaxel, often given alongside vaginal cuff radiation or pelvic radiation. A phase II trial of pelvic radiation “sandwiched” between cycles of carboplatin and paclitaxel reported that this combined approach was well tolerated and effective in patients with completely resected UPSC.¹⁸ Another study of early-stage patients found that adjuvant carboplatin-paclitaxel with intravaginal radiation provided strong five-year outcomes.¹⁹ The challenge is that many patients eventually develop resistance to this chemotherapy combination, which has spurred research into targeted and immunotherapy options.¹³

Recurrence and Prognosis

Even among patients diagnosed at clinical stage I, the recurrence rate for UPSC is roughly 31%, compared to about 6% for non-serous endometrial cancers. Most recurrences happen within two years, and the most common sites are in the abdomen rather than the vaginal cuff, the typical site for endometrioid recurrences. In one series, all UPSC patients who recurred died of their disease, compared to 61% of patients with ordinary adenocarcinomas who recurred.²⁰

For stage II disease, chemotherapy appears to make a substantial difference. Five-year progression-free survival was 86% among chemotherapy-treated patients versus 41% among those who did not receive it, and most recurrences were outside the pelvis (about 70%) and not amenable to further curative treatment.²¹ These numbers underscore why even apparently early-stage UPSC is treated aggressively.

CA-125 and Surveillance After Treatment

The blood marker CA-125 has a limited but potentially useful role in UPSC. In one study of 52 patients, a preoperative CA-125 level above 30 U/mL was linked to advanced-stage disease, lymph node involvement, and omental metastases. However, in that same cohort, an elevated CA-125 was not an independent predictor of recurrence once other factors were accounted for.²²

Where CA-125 may be more telling is in follow-up after remission. A study tracking patients with recurrent UPSC found that even a rise of 10 U/mL within the normal range was associated with disease recurrence. A level at or above 15 U/mL was the strongest predictor of worse progression-free survival on multivariate analysis.²³ The takeaway is that even modest upward trends in CA-125, not just outright elevations, may warrant closer investigation in UPSC patients.

Racial Disparities in Outcomes

UPSC disproportionately affects Black women, who are diagnosed with advanced disease at higher rates.⁵ But the survival gap extends beyond stage at diagnosis. A large analysis spanning more than two decades found that after adjusting for age, stage, surgical treatment, lymph node dissection, radiation, and geographic location, African American patients were consistently 29 to 40% more likely to die of their uterine cancer compared to white patients across three successive time periods from 1988 through 2011.²⁴ That the gap persisted even after accounting for treatment differences suggests biological, socioeconomic, and healthcare-access factors that statistical models cannot fully capture. This disparity has made UPSC a focal point in discussions about equity in gynecologic cancer care.

Hereditary Risk and BRCA Mutations

While most UPSC occurs sporadically, a hereditary component exists. Women who carry BRCA1 or BRCA2 germline mutations face a markedly elevated risk. A multicenter cohort study found that the overall endometrial cancer risk in BRCA1/2 carriers was about 2.8 times higher than in the general population. When researchers broke the numbers down by cancer subtype, the risk increase was far steeper for serous-like histology: nearly 10-fold overall, and about 12.6-fold specifically for BRCA1 carriers.²⁵

The absolute proportion of UPSC patients who carry BRCA1 mutations is small, around 2% in one study of an unselected group, but that rate is higher than expected in a population not enriched for founder mutations. The recommendation arising from this evidence is straightforward: women diagnosed with UPSC who also have a personal or family history of breast cancer should be offered genetic testing for BRCA1 and BRCA2.²⁶ Identifying a mutation has implications not only for the patient’s own management but also for cancer screening in family members.

Circulating Tumor DNA as an Emerging Surveillance Tool

Because UPSC recurs frequently, often in the abdomen where imaging can miss small deposits, there is strong interest in blood-based tests that could catch recurrence earlier. Circulating tumor DNA (ctDNA) is one of the most promising. These are tiny fragments of DNA shed by tumor cells into the bloodstream, and personalized assays can look for the specific mutations present in a patient’s original tumor.

In a study of high-risk endometrial cancer patients, ctDNA detected after surgery was predictive of relapse, with a hazard ratio suggesting a dramatically higher recurrence risk compared to patients whose post-operative blood was ctDNA-negative.²⁷ A separate study focusing specifically on uterine serous carcinoma and carcinosarcoma found that in multiple patients, serial ctDNA testing detected cancer recurrence before it became visible on CT scans or before CA-125 levels rose.²⁸

These studies are still small, and ctDNA testing has not yet become standard practice for UPSC surveillance. But for a cancer where early detection of recurrence could allow treatment to begin months sooner, and where current tools like imaging and CA-125 have clear blind spots, this is one of the more genuinely exciting research frontiers. Whether that lead time translates into meaningfully better survival remains the open question that larger trials are designed to answer.

1
Clinical Obstetrics and Gynecology. Uterine Papillary Serous Carcinoma
2
International Journal of Gynecological Cancer. Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium
3
Karger Publishers. A Rare Case of Uterine Serous Carcinoma: Importance of Early Detection and Comprehensive Treatment in Postmenopausal Women
4
PubMed. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas
5
PubMed. Uterine serous carcinoma: key advances and novel treatment approaches
6
PubMed Central. Endometrial serous carcinoma: A retrospective review of histological features & their clinicopathological association with disease-free survival & overall survival
7
Gynecologic Oncology. Uterine Papillary Serous Carcinoma: Patterns of Metastatic Spread
8
PubMed Central. The role of omentectomy in the surgical treatment of uterine serous carcinoma
9
PubMed Central. Serous endometrial intraepithelial carcinoma: a case report
10
JNCI: Journal of the National Cancer Institute. Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses
11
PubMed Central. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
12
PubMed. Loss of p53 function in uterine papillary serous carcinoma
13
PubMed. A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer
14
PubMed. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma
15
PubMed. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma
16
PubMed. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
17
PubMed Central. A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma
18
PubMed Central. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma
19
PubMed. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer
20
PubMed. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma
21
PubMed. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
22
International Journal of Gynecological Cancer. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
23
PubMed Central. The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer
24
PubMed. Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011
25
JNCI: Journal of the National Cancer Institute. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
26
PubMed Central. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma
27
PubMed Central. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer
28
PubMed Central. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers